Cyxone’s CMO departs the company

Cyxone (publ) announces today that Chief Medical Officer (CMO) Cornel Pater leaves the company with immediate effect due to personal reasons. The planned Phase 2b study in rheumatoid arthritis (RA) is advancing and the intermediate situation will be covered by Cyxone’s management team and medical advisors. Recruitment of a new CMO has started.

“We move forward with the phase 2b study in RA and see no immediate challenge while we scout for a new CMO. I want to thank Cornel for his dedicated work and valuable contributions to Cyxone during his time with us”, comments CEO Tara Heitner.

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on 23 February 2022

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. For more information, please visit www.cyxone.com